Identification and quantification of maturing hematopoietic cell populations in flow cytometry data sets is a complex and sometimes irreproducible step in data analysis. Supervised machine learning algorithms present promise to automatically classify cells into populations, reducing subjective bias in data analysis. We describe the use of support vector machines (SVMs), a supervised algorithm, to reproducibly identify two distinctly different populations of normal hematopoietic cells, mature lymphocytes and uncommitted progenitor cells, in the challenging setting of pediatric bone marrow specimens obtained 1 month after chemotherapy. Four-color flow cytometry data were collected on a FACS Calibur for 77 randomly selected postchemotherapy pediatric patients enrolled on the Children's Oncology Group clinical trial AAML1031. These patients demonstrated no evidence of detectable residual disease and were divided into training (n 5 27) and testing (n 5 50) cohorts. SVMs were trained to identify mature lymphocytes and uncommitted progenitor cells in the training cohort before independent evaluation of prediction efficiency in the testing cohort. Both SVMs demonstrated high predictive performance (lymphocyte SVM: sensitivity >0.99, specificity >0.99; uncommitted progenitor cell SVM: sensitivity 5 0.94, specificity >0.99) and closely mirrored manual cell classifications by two expert-analysts. SVMs present an efficient, automated methodology for identifying normal cell populations even in stressed bone marrows, replicating the performance of an expert while reducing the intrinsic bias of gating procedures between multiple analysts. V C 2016 The Authors. Cytometry Part A published by Wiley Periodicals, Inc. on behalf of ISAC.
INTRODUCTION
DURING the process of monitoring response to acute myeloid leukemia (AML) therapy using flow cytometry, it was noted that patterns of antigen expression of the normal, regenerating hematopoietic cells were remarkably similar from patient to patient, even early postchemotherapeutic treatment. For three separate Children's Oncology Group AML trials over a period of 13 years, standardized four-color panels were used to pattern early stages of hematopoiesis (1, 2) . Using the "difference from normal" flow cytometric approach, low levels of neoplastic leukemia were distinguished from normal regenerating myeloid cells based on the detection of small populations of viable cells exhibiting aberrant antigen expression. These studies comprised the analysis of over 10,000 specimens obtained from >2,300 patients monitored throughout the course of treatment.
Quantifying the variance of gene product (antigen) expression within and between individuals on these recovering bone marrows is complicated by the heterogenous composition of the specimens. There are 11 different lineages of cells that must be identified within the bone marrow, in addition to all stages of maturation from the hematopoietic stem cell to the mature blood cells. As a result, cell populations are not discrete and the proportions of different cell types vary depending upon the rate of hematopoietic reconstitution following therapy. However, the positions of all cell populations in the sixdimensional data space appeared to remain constant.
To quantify the variance of gene product expression without subjective gating bias, the supervised algorithms support vector machines (SVMs) were selected to identify key reference cell populations. This technique defines a multidimensional plane based on a teaching set created by an expert. This plane is then used to identify corresponding cell populations in new, independent patient data sets that combine the exact same parameters based on constancy of position in N-dimensional space. This article describes the efficacy of the SVMs to reproduce the expert-detection of two of the reference populations, mature lymphocytes and uncommitted progenitor cells. Two companion papers then use this approach to determine the variability of gene product expression among normal cells in postchemotherapy regenerating bone marrow specimens.
MATERIALS AND METHODS

Patient Data Set
Patients younger than 21 years with newly diagnosed de novo AML who were enrolled on Children's Oncology Group (COG) AAML1031 were eligible for this study. The trial was conducted in accordance with the Declaration of Helsinki and registered at www.clinicaltrials.gov as NCT01371981. A total of 77 randomly selected, pediatric AML patients obtained approximately 1 month postchemotherapy were identified as having no evidence of residual disease (3). Patients were randomly assigned to training (n 5 27) and testing (n 5 50) cohorts.
Specimen Collection
Bone marrow aspirates were collected in heparin (the preferred anticoagulant) or EDTA. The data were obtained over a period of 3 years and 6 months using three separate flow cytometers, multiple reagent lots, and processed by multiple technicians.
Flow Cytometry
Specimens were processed as routine clinical bone marrows as previously described (1) . Briefly, 100 lL of bone marrow was added to cocktails of pretittered antibodies at room temperature in the dark. Red blood cells were lysed using 3.5 mL of buffered NH 4 Cl (0.83%) at 378C for 5 min before centrifugation at 300G. Cells were then washed with 3 mL of phosphate buffered saline containing 2% fetal calf serum and resuspended to 0.5 mL in 1% paraformaldehyde for analysis on one of three FACS Calibur instruments (Becton Dickinson Biosciences, San Jose, CA). 200,000 events were collected for each tube. The flow cytometers were cross standardized and calibrated using RCP-30A and RFP-30A beads (Spherotech, Lake Forest, IL) with spectral compensation performed using peripheral blood cells labeled with CD4 (SK3, BD) conjugated to fluorescein (FITC), phycoerythrin (PE), peridinin chlorophyll protein (PerCP), or allophycocyanin (APC). Eight combinations of antibodies are presented in Table 1 . The eighth tube was added after the beginning of the study to identify immature B lymphoid precursors/plasmacytic dendritic cells and basophils, so this reagent combination was only implemented in 45 of the 50 patients in the testing cohort.
Support Vector Machines
An expert-analyst (MRL) classified mature lymphocyte and uncommitted progenitor cell populations using Winlist (Verity Software House, Topsham, ME) for all patients in both the training and testing cohorts. All flow-cytometry data Original Article were analyzed in log space, with the exception of forward light scatter (FSC). Expert-classified cell populations from the cohorts were exported from Winlist into R software (4). For both lymphocytes and uncommitted progenitor cells, all data from the training cohort patients were merged to create one file that differentiated cells within the population of interest (11) from the remainder of cells (21) . Log base-10 transformations were computed for right-angle side scatter (SSC), FITC, PE, PerCP, and APC parameters prior to SVM training. The linear range of FSC was scaled to emulate a zero-to-four log scale. An SVM was trained to identify each target population with a radial kernel using the e1071 library (5) . A basic overview of an SVM algorithm is provided in the supplementary data ( Supplementary Fig. 1 ). To manage the computational intensity of training the lymphocyte SVM, 1000 random manually classified lymphocytes (11) and 1,500 random manually classified nonlymphocytes (21) from each patient were merged to form the lymphocyte training data set. Because only support vectors influence the SVM decision boundary, the 1,500 nonlymphocytes in each patient were selected to enrich the training cohort with potential support vectors. Therefore, the nonlymphocytes were selected based on similar properties to the lymphocytes: a SSC of <2 log units and a CD45 intensity >2 log units. Similar exclusion procedures have been utilized to enrich datasets for support vectors and reduce the training time of SVMs (6,7). To manage the computational intensity of the uncommitted progenitor cell SVM training, manually classified uncommitted progenitor cells (11) and similar nonuncommitted progenitor cells (21) with a CD34 intensity >2 log units from each patient were merged to form the uncommitted progenitor cell training set. Because 27 patients comprised each training data set, a ninefold leave-three-out cross validation was applied on the training data to determine optimal C and c parameters for both SVMs (8) . 
Statistics
Sensitivity and specificity were used to evaluate prediction efficiency, and were calculated according to the standard definitions, where the manual classifications of the expert analyst (MRL) were regarded as the true classifications.
Because predicted cell populations were often small when compared to the total number of collected events, prediction efficiency was also evaluated with the Matthews correlation coefficient (MCC) (9) . The MCC is a balanced measure of the quality of a binary prediction algorithm even when classes are of different sizes. The MCC returns a value between 21 and 1, where 1 represents a perfect prediction, 0 represents a random prediction, and 21 represents complete disagreement between the prediction and observation, and is calculated by the following definition:
RESULTS
SVM Training
Two different cell types were selected to test the performance of SVMs in a complex data set of normal regenerating bone marrow cells following chemotherapy. The first group of cells, mature lymphocytes, is relatively straightforward for an expert analyst to identify, and is presented to demonstrate the efficacy of classifying a homogenous, discrete, relatively frequent cell population with SVMs. The second group of cells, uncommitted progenitor cells, is challenging to identify as this population is a heterogeneous, nonlinearly separable population of infrequent cells.
SVMs were initially trained to identify each target population in regenerating bone marrow using the combination of Original Article parameters found in Tube 4 of the antibody panel (Table 1) : linear FSC, log SSC, log CD14 (FITC), log CD33 (PE), log CD45 (PerCP), and log CD34 (APC). Lymphocyte cell populations are identified as a distinct, homogenous cluster of events with high CD45 intensity and low SSC (Fig. 1A ). This population of cells is of relatively high frequency, typically comprising 5-20% of cells in the bone marrow (Fig. 1B ). An expert-analyst manually identified this discrete lymphocyte population by CD45 versus log SSC gating in combination with FSC in the training cohort patients, and these manual classifications were used to train and cross-validate the lymphocyte SVM. The inclusion of CD14 (FITC) and CD33 (PE) parameters did not further improve predictive performance in SVM training (data not shown). Consequently, mature lymphocyte SVM training was only performed with FSC, SSC, CD45, and CD34 parameters.
In contrast, uncommitted progenitor cells are not discrete but a continuous population. These cells include the hematopoietic stem cells and multipotent progenitor cells that have not yet expressed any lineage-associated surface gene products (10, 11) . Uncommitted progenitor cells are defined by a homogenous high expression of the key antigen, CD34, and coexpression of CD33 (Fig. 1C) . CD33 changes in intensity once the uncommitted progenitors decide a maturational path, increasing in CD33 expression for monocytes and neutrophils, decreasing in CD33 expression for plasmacytic dendritic cells, or rapidly losing CD33 for lymphoid progenitor cells. An expert analyst manually identified the uncommitted progenitor population by gating the brightest intensity CD34 cells before the gain or loss of CD33 (Fig. 1C) . This population is of noticeably lower frequency than the lymphocyte population, typically comprising 0.5-2% of all cells in the bone marrow (Fig. 1D ). This manual classification was completed for all training cohort patients and used to train and cross-validate the uncommitted progenitor cell SVM. All six parameters were necessary to train this SVM with maximal prediction performance (data not shown). 
Qualitative Evaluation of SVM Population Predictions
After training, the two SVMs were applied to identify lymphocytes and uncommitted progenitor cells in the independent test cohort. Algorithmic predictions were first qualitatively evaluated. The SVM-predicted populations were compared to the expert analyst's test cohort classifications in each test patient for the lymphocytes ( Fig. 2A) and uncommitted progenitor cells (Fig. 2B) . The population predictions agreed with the corresponding expert-classifications, and the majority of cells were correctly identified in each target population. However as expected, some misclassifications occurred, and these discrepant predictions were located at the edges, rather than the center, of the SVM decision boundary. Additionally, histograms of key antigens were compared between SVM-predictions and all other events in each test patient. In the display of CD45 intensities of all cells, a uniform, bright CD45 population can be readily visualized (Fig. 2C ). This population is comprised almost entirely of SVM-classified lymphocytes (with the remainder of bright CD45 positive cells identified as predominantly monocytes). In contrast, initial analysis of all CD34 positive cells (with an intensity greater than two log units) revealed a heterogeneous distribution of CD34 intensities (Fig. 2D) . The SVM-classified uncommitted progenitor cells can be identified as a homogenous high intensity CD34 peak clearly distinguishable within this heterogeneous population.
Quantitative Evaluation of SVM Population Predictions
Classification performance of each SVM was quantitatively evaluated. Each SVM prediction was compared to the independent expert classification for all patients in the testing cohort. The average sensitivity, specificity, and MCC of the lymphocyte SVM and the uncommitted progenitor cell SVM demonstrated remarkably high predictive performance by all three metrics (Table 2) . A similar comparison was made to a second expert (LP) who analyzed the same data set with instructions to identify the lymphocytes and uncommitted progenitor cells, without disclosing the details of how boundaries were established. The average sensitivity, specificity, and MCC of the classifications of the second expert were computed in comparison to the first expert ( Table 2 ). The SVMs and second expert (LP) demonstrated similar performance replicating the gates of the first expert (MRL). 
Original Article
Classification performance was additionally evaluated by correlating population frequency and average surface gene product intensities between each SVM-predicted cell population and the expert-identified cell population in the test cohort. R 2 values were calculated to evaluate how well the data fit a hypothesized linear model (SVM 5 Expert) (Figs. (3) and (4)). On a four-decade scale, the relationship between the SVM and the expert analyst are essentially indistinguishable. Within the intensity and frequency regions of interest, small discrepancies between the SVM and expert can be identified. However, 97% of lymphocyte SVM intensities and 92% of uncommitted progenitor cell SVM intensities were within 0.05 log units of the expert-characterized intensity, demonstrating the high-functional agreement between the SVM and the expert. A similar high correlation between the two experts analyzing the same dataset was observed (Supplemental Figs.  2 and 3) , suggesting that the SVM and second expert were comparable in replicating the classifications of the first expert.
Replicate Identification of Lymphocytes and Uncommitted Progenitor Cells
In addition to the initial panel of CD14/CD33/CD45/ CD34 (Table 1 , Tube 4), seven other combinations of FITC and PE conjugated antibodies were used to study cell surface gene product relationships in each regenerating bone marrow specimen. Collectively, these unique reagent combinations provided eight replicate analyses in each patient to identify the lymphocytes and uncommitted progenitor cells with SVMs.
The initial lymphocyte SVM was trained using only FSC, SSC, CD45, and CD34 parameters, characteristics which were conserved between the eight reagent combinations. Therefore, the original lymphocyte SVM was applied to classify this cellular population in each of the additional combinations of FITC and PE conjugated-antibodies. In contrast, the initial uncommitted progenitor cell SVM training required both CD14 FITC and CD33 PE parameters to achieve optimal predictive performance. Therefore, this specific SVM could not be applied to any of the other combinations of reagents. Consequently, eight unique SVMs were trained (one for each regent combination) to identify uncommitted progenitor cells. These independently trained SVMs were then applied to identify the uncommitted progenitor cells in each of the eight tubes with different FITC and PE conjugated-antibodies, providing replicate analyses identifying the same cell population but with different SVMs.
For both lymphocytes and uncommitted progenitor cells, replicate intensities of FSC, SSC, and CD45 and replicate cell frequency measurements between the eight SVM-predictions were analyzed in the test cohort. Replicate CD34 intensities were additionally analyzed for uncommitted progenitor cells but not lymphocytes, as the lymphocytes do not express this gene product. The variability in average intensity and frequency between the eight predictions was computed for each patient, and averaged for the test cohort (Table 3 ). The lymphocytes, identified by the same SVM in all eight combinations of antibodies, demonstrated minimal variation of FSC, SSC, and CD45 between the eight populations identified in each patient. In addition, the replicate lymphocyte frequency variation is low, suggesting that a similar proportion of cells were identified in each of the eight replicates. Collectively, this data demonstrates that the lymphocyte-SVM trained using Tube 4 of the reagent panel identified a similar population of cells in each combination of reagents studied. Average sensitivity, specificity, and MCC values were computed by calculating the mean of all sensitivity, specificity, and MCC measurements for the 50 test predictions for both the SVM and expert 2 (LP). Classifications from expert 1 (MRL) were designated as the true classifications. In each test patient, the average FSC, SSC, and CD45 intensities were calculated for the eight lymphocyte and uncommitted progenitor cell predictions. Replicate CD34 intensities were additionally computed for uncommitted progenitor cells but not lymphocytes, as the lymphocytes do not express this gene product. The variation (standard deviation) between these eight measurements was calculated for each test patient and averaged for the test patient cohort. Additionally, the predicted population frequency (predicted events/total events) was calculated for each of the eight predictions. The variation (standard deviation) of the predicted population frequency between the eight predictions was calculated for each patient and averaged for the test patient cohort.
In spite of the independent algorithm-training utilizing different combinations of reagents, each of the eight uncommitted progenitor cell SVMs identified a population of cells with similar low variation of FSC, SSC, CD45, and CD34 within each patient. Although the uncommitted progenitor cells are infrequent, on average comprising 1.2% of cells in the marrow in the test cohort, the variation in frequency between the eight replicate predictions was only 0.2%. Again, this provides strong evidence that a similar proportion of cells were identified in each of the eight replicate tests. Collectively, these data suggests that despite independent SVM training, a remarkably similar population of uncommitted progenitor cells were identified in each tube of the reagent panel, further validating the high efficacy of SVM-identification of this population.
Discussion
To quantify the variance of gene product expression of hematopoietic cell populations in the bone marrow, reference populations must be identified with limited analytical bias. In this manuscript, we show that SVMs present an automated methodology to identify such reference populations with high agreement to the expert. By testing SVMs on pediatric bone marrows postchemotherapy, we studied the efficacy of SVMs in a challenging analytical setting, comprised of stressed, heterogeneous, maturing, multilineage populations of cells. This challenging setting replicates the difficulties of performing clinical flow cytometry analysis for the detection of residual disease based on "difference from normal" (1) . The location of the normal cells in n-dimensional data space is crucial in this approach to detect low levels of cells expressing phenotypic aberrancies (12) (13) (14) .
Each metric of predictive performance evaluated in this manuscript indicates that SVMs closely mirror expert gating designations. First, high sensitivity, specificity, and MCC measurements demonstrated strong agreement between SVM and expert classifications. Second, frequency and mean fluorescent intensity measurements were remarkably correlated between expert-and SVM-identified populations. Third, the low variation of frequency and mean fluorescent intensity measurements for replicate analysis within each individual patient indicates that SVMs reproducibly characterize the same cell population studied with different combinations of reagents, illustrating the power of this algorithm in a stable analytical system. Fourth, the comparison between two experts analyzing the same data set illustrates that the SVM replicates expert-trained classifications as well as a second, independent expert. Collectively, this data shows that SVMs can effectively replicate the expert identification of lymphocytes and uncommitted progenitor cells while reducing analytical bias inherent to manual gating procedures.
The success of population classification using SVMs is dependent on two assumptions. First, quality control of the system must be rigorous to maintain identical data collection on multiple instruments with multiple lots of reagents over an extended period of time, such as the length of a clinical trial. In the data presented here, three separate, cross standardized flow cytometers were used in data collection spanning three and a half years, employing multiple lots of titered reagents. Second, the variability of cellular characteristics between patients must be minimal. As SVMs are trained using only fluorescent and light scattering intensity measurements, each population's collective surface gene product expression must reside in a unique and constant region within the sixdimensional space to be efficiently identified by the SVM. In this test system, the location of the mature lymphocytes and the normal uncommitted progenitor cells were sufficiently stable to identify the target populations even in stressed regenerating bone marrow specimens after chemotherapeutic treatment. Although, the cellular frequency of these populations varied significantly, the location of these populations with regard to their assayed cellular characteristics remained stable enough for the trained SVM to replicate the expert analysis for each test patient.
There are limitations associated with SVM analysis of flow cytometry data. SVMs by definition only perform predictions in the two-class setting, distinguishing between the target population and all other events. Hence, identifying multiple cell populations within the same patient requires the training of multiple unique SVMs. In addition, several unique SVMs are sometimes needed to identify the same population of cells in different combinations of reagents, as demonstrated by the identification of the uncommitted progenitor cells. The training of multiple SVMs can be a time-consuming process for the expert analyst and computationally intensive. Further, the selection of kernel and cost parameters can affect the performance of an SVM. Cross-validation of training data can be used to estimate predictive performance for numerous combinations of input variables, allowing for the identification of kernel and cost parameters that lead to better performance. Yet cross-validation can likewise be computationally intensive for multiple SVMs in a large training cohort. Because only support vectors influence the SVM-decision boundary, computational time can be reduced by training the algorithm on a subset of the data with characteristics similar to the population of interest (6, 7) . For example, the uncommitted progenitor cell SVM was trained only on cells with CD34 intensities >2 log units. In the testing cohort, SVM-identification of both the lymphocytes and uncommitted progenitor cells averaged 42 sec on a machine with 16GB of RAM in patients with 200,000 collected events.
The field of automated flow cytometry analysis contains numerous supervised, semisupervised, and unsupervised algorithms to identify populations of hematopoetic cells (15) (16) (17) (18) (19) (20) (21) . However, the majority of existing algorithms include unsupervised or clustering components to assemble high-density groups of data points into populations (22) (23) (24) (25) . SVMs cannot reproducibly identify cell populations in which gene product expression varies substantially between patients. In such a setting, unsupervised algorithms may better identify clusters of cells independent of consistent fluorescent intensity measurements. Instead, SVMs are predicated on identifying constant quantitative surface gene product expression patterns found on biological cell populations independent of cell frequency. SVMs have shown success in classifying cell populations in Original Article peripheral blood (26) and murine bone marrow (27) , and even at identifying acute lymphoblastic leukemia with reproducible phenotypes (28) . In this manuscript, we extend this approach to identify crucial reference populations in postchemotherapy pediatric bone marrow specimens with reagent combinations used to study over 10,000 patients in three large clinical trials.
SVMs present an automated methodology to identify reference populations with high expert agreement. This experttrained algorithm exhibits high predictive performance in the challenging specimen type of pediatric bone marrow after chemotherapy. Hence, SVMs present a powerful tool to precisely quantify the variation of gene product expression with limited analytic bias.
